Publisher of Iranian Journals and Conference Proceedings

Please waite ..
Publisher of Iranian Journals and Conference Proceedings
Login |Register |Help |عضویت کتابخانه ها
Paper
Title

Evaluation of the Effects of Letrozole in Combination with Neoadjuvant Chemotherapy on Clinical Response Rate of Breast Cancer

مجله پزشکی قلب و قفسه سینه، دوره: 9، شماره: 1
Year: 1400
COI: JR_JCTM-9-1_005
Language: EnglishView: 116
This Paper With 7 Page And PDF Format Ready To Download

Buy and Download

با استفاده از پرداخت اینترنتی بسیار سریع و ساده می توانید اصل این Paper را که دارای 7 صفحه است به صورت فایل PDF در اختیار داشته باشید.
آدرس ایمیل خود را در کادر زیر وارد نمایید:

Authors

Zahra Mozahheb - Department of Medical Oncology and Hematology, Imam Reza Hospital, Mashhad, Iran.
Abolghasem Alahyari - Department of Medical Oncology and Hematology, Imam Reza Hospital, Mashhad, Iran.
Seyyedeh Fatemeh Seyyedi Khabbaz - Department of Medical Oncology and Hematology, Imam Reza Hospital, Mashhad, Iran
Asieh Sadat Fattahi - Minimally Invasive and Endoscopic Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Mona Najaf Najafi - Department of Statistics and Social Medicine, Imam Reza Hospital, Mashhad, Iran.

Abstract:

AbstractThis randomized clinical trial was aimed to assess the efficacy of neoadjuvant letrozole in combination with standard neoadjuvant chemotherapy regimen on clinical response rate of hormone receptor positive locally advanced breast cancer.In this randomized clinical study, ۴۲ female patients, ≥ ۱۸ years, with clinical stage IIB-IIIC (T۱-۴, N۰-۳, M۰), pathologically proven hormone receptor positive and HER۲ negative, invasive ductal carcinoma of breast, were randomly assigned to receive standard neoadjuvant chemotherapy alone (control group) or letrozole ۲.۵ mg/d (in association with goserlin in premenopausal patients) concurrent with standard neoadjuvant chemotherapy (study group). Standard neoadjuvant chemotherapy regimen has consisted of ۴ cycles of doxorubicin (۶۰mg/m۲) and cyclophodphamide (۶۰۰mg/m۲), followed by ۴ cycles of paclitaxel (۱۷۵mg/m۲) every two weeks.At the beginning of the study all patients underwent thorough exmination of breast mass and axillary lymph nudes by palpation and ultrasonography. At the end of the study response rates were also evaluated by palpation and ultrasonography and subsequently patients were referred for surgury. Pathologic response rates were also evaluated on surgical specimens. All of the clinical, ultrasonographic and pathologic examinations during the trial were performed by a single specialist. Finally all the data were analysed statistically.Overall clinical response rates in breast were ۹۵.۲%, in both study and control group. Overall clinical response rates in axilla were ۸۰.۹% and ۷۶.۲% in study and control group respectively. Similarly, overall radiologic complete response rates in breast and axilla were ۹۵.۲% and ۷۶.۲% respectively in both study and control group. Totally, the comparison of overall clinical and radiologic response rates in th breast and axilla, showed no significant difference between control and study group (p>۰.۰۵).The addition of letrozol to standard neoadjuvant chemotherapy regimen was not associated with higher clinical and radiologic response rates in patients with locally advanced hormon receptor positive breast cancer.Keywords: Neoadjuvant chemotherapy, Letrozole, Locally advanced breast cancer

Keywords:

Neoadjuvant chemotherapy , Letrozole , locally advanced breast cancer

Paper COI Code

This Paper COI Code is JR_JCTM-9-1_005. Also You can use the following address to link to this article. This link is permanent and is used as an article registration confirmation in the Civilica reference:

https://civilica.com/doc/1186906/

How to Cite to This Paper:

If you want to refer to this Paper in your research work, you can simply use the following phrase in the resources section:
Mozahheb, Zahra and Alahyari, Abolghasem and Seyyedi Khabbaz, Seyyedeh Fatemeh and Fattahi, Asieh Sadat and Najaf Najafi, Mona,1400,Evaluation of the Effects of Letrozole in Combination with Neoadjuvant Chemotherapy on Clinical Response Rate of Breast Cancer,https://civilica.com/doc/1186906

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :

  • 1. Winer EP. Malignant tumors of the breast. Cancer: principles ...
  • 2. Klein J, Tran W, Watkins E, Vesprini D, Wright ...
  • 3. Sinn HP, Helmchen B, Wittekind CH. TNM classification of ...
  • 4. Garg PK, Prakash G. Current definition of locally advanced ...
  • 5. Bardia A, Dixon JM. Neoadjuvant therapy for newly diagnosed ...
  • 6. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred ...
  • 7. Housaindokht MR, Chamani J, Saboury AA, Moosavi-Movahedi AA, Bahrololoom ...
  • 8. Sharifi-Rad A, Mehrzad J, Darroudi M, Saberi MR, Chamani ...
  • 9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent ...
  • 10. Schick P, Goodstein J, Moor J, Butler J, Senter ...
  • 11. Torrisi R, Bagnardi V, Rotmensz N, Scarano E, Iorfida ...
  • 12. Mohammadianpanah M, Ashouri Y, Hoseini S, Amadloo N, Talei ...
  • 13. Redden MH, Fuhrman GM. Neoadjuvant chemotherapy in the treatment ...
  • 14. Lari, S., Attaran, D., RokniYazdi, H., Towhidi, M., Shadkam, ...

Research Info Management

Certificate | Report | من نویسنده این مقاله هستم
این Paper در بخشهای موضوعی زیر دسته بندی شده است:

اطلاعات استنادی این Paper را به نرم افزارهای مدیریت اطلاعات علمی و استنادی ارسال نمایید و در تحقیقات خود از آن استفاده نمایید.

Share this page

More information about COI

COI stands for "CIVILICA Object Identifier". COI is the unique code assigned to articles of Iranian conferences and journals when indexing on the CIVILICA citation database.

The COI is the national code of documents indexed in CIVILICA and is a unique and permanent code. it can always be cited and tracked and assumed as registration confirmation ID.

Support